The analysis suggests tirzepatide may beat semaglutide 7.2 mg for weight loss, but she points out the two drugs were never tested against each other in one trial.
Recap by typeshit. Post by @dr_janelle_md on Instagram.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
Local news team runs a verify segment on retatrutide, the experimental weight-loss drug people are buying without approval.
Box Life Magazine says new Oxford research paints a sobering picture of GLP-1 weight loss drugs like Ozempic and Wegovy, but its post gives no findings and is gated behind comment bait.
Loading…